Aurobindo Pharma is expanding footprint in South America with a new subsidiary in Chile

Aurobindo Pharma Limited on Thursday announced the incorporation of a new wholly-owned subsidiary, Eugia Pharma Chile SpA, in Chile, which is a strategic move to expand its pharmaceutical business in South America. Eugia Pharma Chile SpA is a wholly owned subsidiary of Eugia Pharma BV, which is itself fully owned by Aurobindo Pharma. The Chilean company was officially incorporated on October 7, 2025, with signed formation documents received on October 22, 2025. This initiative is part of Aurobindo Pharma’s broader strategy to strengthen its presence in international markets, particularly in the pharmaceutical sector, it said in a stock exchange filing. The transaction involves a 100% cash subscription to the share capital, with an initial subscription of CLP 1,000,000 (approximately USD 1,050), divided into 100 shares with a nominal value of CLP 10,000 each. The transaction was executed at arm’s length, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which require listed entities to disclose material events affecting their operations or financial position. Chile’s pharmaceutical sector offers significant growth potential, and Aurobindo Pharma’s expansion in the country is in line with its strategy to diversify geographically and improve its product offerings. While the new subsidiary does not yet have a turnover history, Aurobindo Pharma’s experience in the global pharmaceutical industry positions it well to capitalize on opportunities in the Chilean market. In Thursday’s session, shares of Aurobindo Pharma closed 0.19% lower at ₹1098.95 apiece, while the benchmark Sensex closed 0.15% higher at 84,556.40. About Eugia Pharma Eugia Pharma focuses on the development and marketing of specialty generic injectables and oncology products. Its portfolio includes a wide variety of injectable formulations, including Penems, Penicillin, Cephalosporins, ophthalmic preparations, inhalation solutions (Respules), oncology drugs and hormonal therapies, according to the company’s website. Disclaimer: This article was generated using AI tools and underwent editorial review for clarity and coherence.